Financials data is unavailable for this security.
View more
Year on year Ondine Biomedical Inc grew revenues 88.56% from 638.00k to 1.20m while net income improved from a loss of 19.37m to a smaller loss of 14.41m.
Gross margin | 60.04% |
---|---|
Net profit margin | -873.56% |
Operating margin | -893.82% |
Return on assets | -249.74% |
---|---|
Return on equity | -685.59% |
Return on investment | -597.99% |
More ▼
Cash flow in CADView more
In 2023, cash reserves at Ondine Biomedical Inc fell by 10.13m. Cash Flow from Financing totalled 3.79m or 314.63% of revenues. In addition the company used 13.65m for operations while cash used for investing totalled 177.00k.
Cash flow per share | -0.0345 |
---|---|
Price/Cash flow per share | -- |
Book value per share | 0.00004 |
---|---|
Tangible book value per share | 0.00004 |
More ▼
Balance sheet in CADView more
Current ratio | 0.8043 |
---|---|
Quick ratio | 0.4828 |
Total debt/total equity | 18.47 |
---|---|
Total debt/total capital | 0.9487 |
More ▼